Home >   Products   >  Advanced Search

(CAS RN:71939-50-9 Product Number:D3793)



General Information

Product Number D3793

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(HPLC)
Storage Temperature 0-10°C
M.F. / M.W. C15H24O5=284.35
CAS RN 71939-50-9
Related CAS RN
MDL Number MFCD00274495
Packaging and Container
  • Product Details
  • Safety & Regulations


Appearance White to Almost white powder to crystal
Purity(HPLC)(CAD) min. 98.0 %(Anomeric total)

Data of Reference

mp 153°C(dec.)(lit.)


Reaxys-RN 5813803
PubChem SID 87561556
Merck Index(14) 817
RTECS# KD4165550

Transport Information

HS Number 2932990090


Dihydroartemisinin: An Active Metabolite of Antimalaria Artesunate

Dihydroartemisinin is an active metabolite of artesunate [A2191] which is a semi-synthetic derivative of artemisinin [A2118]. Dihydroartemisinin and its analogs have high efficacy against Plasmodium falciparum in the blood stages of the disease. The exact mechanism of action is still not clear, while the endoperoxide (O-O) subunit of the trioxane ring is critical for antimalarial activity. Several lines of evidence indicate that the O-O bond is easily broken by Fe2+, generating a number of reactive radicals oxidatively damage parasite. In clinical, dihydroartemisinin is often used as a combination agent with a partner agent which has a long half-life, such as piperaquine. In addition, after 2000’s, the anti-tumor activities of dihydroartemisinin have been reported. (The product is for research purpose only.)


PubMed Literature

Page Top